When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Betaxolol has no significant effect on pulmonary function as measured by Forced Expiratory Volume in one second (FEV1,), Forced Vital capacity (FVC), FEV1 / FVC and no evidence of
cardiovascular beta-adrenergic-blockade during exercise was observed.
When instilled in the eye, Betaxolol has the action of reducing elevated as well as normal intraocular pressure (IOP), whether or not accompanied by glaucoma. Ophthalmic Betaxolol has little or no effect on the constriction of the pupil and minimal effect on pulmonary and cardiovascular parameters.Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss Betaxolol has the action of reducing elevated as well as normal intraocular pressure, and the mechanism of ocular hypotensive action appears to be a reduction of aqueous humour production as demonstrated by tonography and aqueous fluorophotometry has been added Section 5.2 - Information on plasma concentrations has been added Section 5.3 - Information on post-implantation loss added Section 9 - Date of first authorisation and last renewal amended Section 10 - Date of revision changed to October 2007
Common: discomfort
Uncommon: tearing
Rare: decreased corneal sensitivity, erythema, itching, corneal punctate staining, keratitis, aniscoria and photophobia
Systemic reactions following topical administration of betaxolol have been rarely reported.